Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-12-2017 | Letter to the Editor

To block it, or not to block it?

Author: Artur Wnorowski

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2017

Excerpt

To Editor, …

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol 29:2635–2644. doi:10.1200/JCO.2010.33.5422 CrossRef

Bruzzone A, Sauliere A, Finana F, Senard JM, Luthy I, Gales C (2014) Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals. FASEB J 28:1342–1354. doi:10.1096/fj.13-239285 CrossRefPubMed

Carie AE, Sebti SM (2007) A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 26:3777–3788. doi:10.1038/sj.onc.1210172 CrossRefPubMed

Chen TC, Hinton DR, Zidovetzki R, Hofman FM (1998) Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest 78:165–174PubMed

Coelho M, Soares-Silva C, Brandao D, Marino F, Cosentino M, Ribeiro L (2017) β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives. J Cancer Res Clin Oncol 143:275–291 doi:10.1007/s00432-016-2278-1 CrossRefPubMed

Eskander R, Bessonova L, Chiu C, Ward K, Culver H, Harrison T, Randall L (2012) Beta blocker use and ovarian cancer survival: a retrospective cohort study. Gynecol Oncol 127:S21 doi:10.1016/j.ygyno.2012.07.059 CrossRef

Gargiulo L et al (2014) Differential beta(2)-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. Oncotarget 5:10058–10069CrossRefPubMedPubMedCentral

Hilal-Dandan R, Knollman B, Brunton L (2017) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition. McGraw-Hill Education

Johannesdottir SA, Schmidt M, Phillips G, Glaser R, Yang EV, Blumenfeld M, Lemeshow S (2013) Use of β-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer 13:85. doi:10.1186/1471-2407-13-85 CrossRefPubMedPubMedCentral

Lemeshow S et al (2011) beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20:2273–2279. doi:10.1158/1055-9965.EPI-11-0249 CrossRefPubMedPubMedCentral

Schmidt SA, Schmidt M (2016) Beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias? Cancer 122:324–325. doi:10.1002/cncr.29721 CrossRefPubMed

Skalhegg BS, Tasken K (2000) Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front Biosci J Virtual Library 5:D678–D693

Strell C, Niggemann B, Voss MJ, Powe DG, Zanker KS, Entschladen F (2012) Norepinephrine promotes the beta1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROalpha release. Mol Cancer Res MCR 10:197–207. doi:10.1158/1541-7786.MCR-11-0130 CrossRefPubMed

Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492–499. doi:10.1093/aje/kwm324 CrossRefPubMed

Sullivan KG, Levin M (2016) Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen. J Anatomy 229:483–502 doi:10.1111/joa.12467 CrossRef

Sun F et al (2015) β2-Adrenoreceptor-mediated proliferation inhibition of embryonic pluripotent stem cells. J Cell Physiol 230:2640–2646. doi:10.1002/jcp.24937 CrossRefPubMed

Toll L et al (2011) β2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther 336:524–532. doi:10.1124/jpet.110.173971 CrossRefPubMedPubMedCentral

Watkins JL et al (2015) Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121:3444–3451. doi:10.1002/cncr.29392 CrossRefPubMedPubMedCentral

Weberpals J, Jansen L, Carr PR, Hoffmeister M, Brenner H (2016) Beta blockers and cancer prognosis—the role of immortal time bias: a systematic review and meta-analysis. Cancer Treatment Rev 47:1–11 doi:10.1016/j.ctrv.2016.04.004 CrossRef

Wnorowski A, Jozwiak K (2014) Homo- and hetero-oligomerization of β2-adrenergic receptor in receptor trafficking, signaling pathways and receptor pharmacology. Cell Signal 26:2259–2265. doi:10.1016/j.cellsig.2014.06.016 CrossRefPubMed

Wnorowski A et al (2015) Activation of β2-adrenergic receptor by (R,R′)-4′-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells. Cell Signal 27:997–1007. doi:10.1016/j.cellsig.2015.02.012 CrossRefPubMedPubMedCentral

Title: To block it, or not to block it?
Author: Artur Wnorowski
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2400-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2017

Reviewer Acknowledgements 2017

Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC)

Karyopherin α-2 is a reliable marker for identification of patients with high-risk stage II colorectal cancer

Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria

Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia

Survival benefit of pelvic and paraaortic lymphadenectomy in high-grade endometrial carcinoma: a retrospective population-based cohort analysis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage